The table below shows GeneDx Holdings Corp.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$33.28M
-$28.50M
-$180.15M
-$319.15M
-$190.43M
-$93.13M
Capital expenditure
$19.02M
$5.49M
$5.25M
$7.16M
$9.40M
$24.09M
Investing cash flow
-$61.52M
-$30.13M
-$43.73M
-$141.33M
-$20.79M
-$31.97M
Dividends paid
-
-
-
-
WGS operating cash flow (10-K history)
GeneDx Holdings Corp. reported operating cash flow of $33.28M for fiscal year 2025. That is up 216.8% from -$28.50M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow grew from -$18.73M (FY 2019) to $33.28M. Figures come from the company's audited annual reports as filed with the SEC.